13-Mar-2026
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Business Wire (Thu, 12-Mar 4:05 PM ET)
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Business Wire (Tue, 3-Mar 4:05 PM ET)
Business Wire (Mon, 2-Mar 4:05 PM ET)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Business Wire (Mon, 23-Feb 4:05 PM ET)
Business Wire (Wed, 4-Feb 4:05 PM ET)
Business Wire (Mon, 2-Feb 4:05 PM ET)
Business Wire (Tue, 13-Jan 9:00 AM ET)
Business Wire (Thu, 18-Dec 4:05 PM ET)
Acadia’s Phase 3 COMPASS PWS Trial Falls Short—but Pipeline and Revenue Projections Remain Strong
Market Chameleon (Wed, 24-Sep 3:57 AM ET)
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Acadia Pharmaceuticals trades on the NASDAQ stock market under the symbol ACAD.
As of March 13, 2026, ACAD stock price declined to $20.61 with 1,318,942 million shares trading.
ACAD has a beta of 1.25, meaning it tends to be more sensitive to market movements. ACAD has a correlation of 0.21 to the broad based SPY ETF.
ACAD has a market cap of $3.45 billion. This is considered a Mid Cap stock.
Last quarter Acadia Pharmaceuticals reported $284 million in Revenue and $.14 earnings per share. This fell short of revenue expectation by $-9 million and exceeded earnings estimates by $.01.
In the last 3 years, ACAD traded as high as $33.99 and as low as $13.40.
The top ETF exchange traded funds that ACAD belongs to (by Net Assets): IJR, VTI, VB, XBI, FBT.
ACAD has outperformed the market in the last year with a return of +22.8%, while the SPY ETF gained +21.4%. However, in the most recent history, ACAD shares have underperformed the stock market with its stock returning -24.1% in the last 3 month period and -16.1% for the last 2 week period, while SPY has returned -2.6% and -3.5%, respectively.
ACAD support price is $20.56 and resistance is $21.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACAD shares will trade within this expected range on the day.
